Therapy with efavirenz plus indinavir in patients with extensive prior nucleoside reverse-transcriptase inhibitor experience: A randomized, double-blind, placebo-controlled trial

Journal of Infectious Diseases

Volumn 183, Issue 3, 2001, Pages 392-400

  Haas, David W ^a   Fessel, W Jeffrey ^b   Delapenha, Robert A ^c   Kessler, Harold ^d   Seekins, Daniel ^e   Kaplan, Mark ^f   Ruiz, Nancy M ^g   Ploughman, Lynn M ^g   Labriola, Dominic F ^g   Manion, Douglas J ^g  

^a VANDERBILT UNIVERSITY   (United States)

^b KAISER PERMANENTE MEDICAL CENTER   (United States)

^c HOWARD UNIVERSITY   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e St Joseph's Comprehensive Research Center   (United States)

^f North Shore LIJ Health System   (United States)

^g DUPONT COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INDINAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIREMIA;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME;

EID: 0035253459     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/318083     Document Type: Article

References (38)

1. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
2. Plasma viral load and CD4 lymphocytes as prognostic markers of HIV-1 infection
3. High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR
4. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
5. HIV-1 RNA levels and the development of clinical disease
6. Changing the natural history of HIV disease
7. 3
8. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
9. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic milliliter or less
10. + lymphocyte count improves assessment of antiretroviral therapeutic response
11. - lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure
12. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
13. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up
14. Viral dynamics of HIV: Implications for drug development and therapeutic strategies
15. HIV viral load markers in clinical practice
16. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents
17. Factors that predict incomplete virologic response to protease inhibitor-based antiretroviral therapy
18. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients
19. Mutations in retroviral genes associated with drug resistance
20. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
21. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)
22. Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase
23. Clinical experience with non-nucleoside reverse transcriptase inhibitors
24. Structure of the binding site for non-nucleoside inhibitors of the reverse transcriptase of HIV-1
25. Crystal structure at 3.5A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
26. L-743, 726 (DMP 266): A novel, highly potent non-nucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase
27. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection
28. Designs for group sequential tests
29. + cells per cubic millimeter
30. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients
31. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
32. Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: Results of AIDS Clinical Trials Group protocol 370